| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10010381AEP2314316A1 (en) | 2002-04-05 | 2003-04-07 | Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors |
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37040702P | 2002-04-05 | 2002-04-05 | |
| US370407P | 2002-04-05 | ||
| PCT/US2003/010749WO2003086289A2 (en) | 2002-04-05 | 2003-04-07 | Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors |
| Publication Number | Publication Date |
|---|---|
| EP1494714A2 EP1494714A2 (en) | 2005-01-12 |
| EP1494714A4true EP1494714A4 (en) | 2008-03-05 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP10010381AWithdrawnEP2314316A1 (en) | 2002-04-05 | 2003-04-07 | Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors |
| EP03746653AWithdrawnEP1494714A4 (en) | 2002-04-05 | 2003-04-07 | Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP10010381AWithdrawnEP2314316A1 (en) | 2002-04-05 | 2003-04-07 | Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors |
| Country | Link |
|---|---|
| US (6) | US7718776B2 (en) |
| EP (2) | EP2314316A1 (en) |
| JP (5) | JP4761710B2 (en) |
| AU (1) | AU2003243139B2 (en) |
| CA (1) | CA2481074A1 (en) |
| MX (1) | MXPA04009681A (en) |
| PL (1) | PL375041A1 (en) |
| WO (1) | WO2003086289A2 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69740107D1 (en) | 1996-12-23 | 2011-03-10 | Immunex Corp | RECEPTOR ACTIVATOR OF NF-KAPPA B, RECEPTOR IS A MEMBER OF THE TNF RECEPTOR SUPERFAMILY |
| EP0911342B2 (en)* | 1997-04-15 | 2013-05-22 | Daiichi Sankyo Company, Limited | Novel protein and process for producing the same |
| PL190092B1 (en) | 1997-04-16 | 2005-10-31 | Amgen Inc | Osteoprotegeric bonding proteins and receptors |
| US6316408B1 (en)* | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| ATE412746T1 (en) | 1998-05-14 | 2008-11-15 | Immunex Corp | METHOD FOR INHIBITING THE EFFECT OF OSTEOCLASTS |
| US20030103978A1 (en)* | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
| DE60235989D1 (en)* | 2001-06-26 | 2010-05-27 | Amgen Fremont Inc | ANTIBODIES AGAINST OPGL |
| JP4761710B2 (en) | 2002-04-05 | 2011-08-31 | アムジェン インコーポレイテッド | Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors |
| SI2248899T1 (en) | 2003-03-19 | 2015-07-31 | Biogen Ma Inc. | NOGO receptor binding protein |
| JP4960865B2 (en) | 2004-06-24 | 2012-06-27 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Treatment of conditions related to demyelination |
| ES2414460T3 (en) | 2004-08-04 | 2013-07-19 | Amgen Inc. | Antibodies for Dkk-1 |
| AU2012272950B2 (en)* | 2005-06-14 | 2015-09-17 | Amgen Inc. | Self-buffering protein formulations |
| US20080311078A1 (en)* | 2005-06-14 | 2008-12-18 | Gokarn Yatin R | Self-Buffering Protein Formulations |
| CA2614421A1 (en) | 2005-07-08 | 2007-01-18 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
| US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| ES2397441T5 (en) | 2006-02-13 | 2022-09-14 | Daiichi Sankyo Co Ltd | Polynucleotide and polypeptide sequences involved in the bone remodeling process |
| JP5167155B2 (en)* | 2006-03-09 | 2013-03-21 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | Compositions and methods related to profiling of multiple cell lines based on peptide bonds |
| EP1901068A1 (en)* | 2006-09-15 | 2008-03-19 | Boehringer Ingelheim Pharma GmbH & Co. KG | Methods of selecting cell clones |
| US20080268470A1 (en)* | 2006-09-15 | 2008-10-30 | Hitto Kaufmann | Methods of selecting cell clones |
| US8128926B2 (en)* | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
| NZ583282A (en) | 2007-08-21 | 2012-09-28 | Amgen Inc | Human c-fms antigen binding proteins |
| PT2206727E (en) | 2007-10-11 | 2015-08-05 | Daiichi Sankyo Co Ltd | Antibody targeting osteoclast-related protein siglec-15 |
| WO2009048605A1 (en)* | 2007-10-11 | 2009-04-16 | Biogen Idec Ma Inc. | Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists |
| WO2009061500A1 (en)* | 2007-11-08 | 2009-05-14 | Biogen Idec Ma Inc. | Use of lingo-4 antagonists in the treatment of conditions involving demyelination |
| US8058406B2 (en) | 2008-07-09 | 2011-11-15 | Biogen Idec Ma Inc. | Composition comprising antibodies to LINGO or fragments thereof |
| AR073072A1 (en) | 2008-08-19 | 2010-10-13 | Regeneron Pharma | HUMAN ANTIBODIES FOR THE BINDING OF THE HUMAN NF-KB RECEIVER ACTIVATOR (RANKL) |
| US20100082438A1 (en)* | 2008-10-01 | 2010-04-01 | Ronnie Jack Garmon | Methods and systems for customer performance scoring |
| MY152033A (en) | 2009-04-09 | 2014-08-15 | Daiichi Sankyo Co Ltd | Anti-siglec-15 antibody |
| WO2011017294A1 (en)* | 2009-08-07 | 2011-02-10 | Schering Corporation | Human anti-rankl antibodies |
| EP2467156B1 (en)* | 2009-08-17 | 2017-11-01 | Tracon Pharmaceuticals, Inc. | Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents |
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| EP2625205A2 (en) | 2010-10-05 | 2013-08-14 | Daiichi Sankyo Company, Limited | Antibody targeting osteoclast-related protein siglec-15 |
| US9464133B2 (en) | 2012-03-30 | 2016-10-11 | Daiichi Sankyo Company, Limited | CDR-modified anti-Siglec-15 antibody |
| HK1206636A1 (en)* | 2012-04-02 | 2016-01-15 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
| WO2013173364A2 (en) | 2012-05-14 | 2013-11-21 | Biogen Idec Ma Inc. | Lingo-2 antagonists for treatment of conditions involving motor neurons |
| EA201590247A1 (en) | 2012-07-19 | 2015-10-30 | Алетиа Байотерапьютикс Инк. | ANTIBODIES TO SIGLEC-15 |
| UA115789C2 (en) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Antibody formulations and uses thereof |
| UY35148A (en) | 2012-11-21 | 2014-05-30 | Amgen Inc | HETERODIMERIC IMMUNOGLOBULINS |
| US9708375B2 (en) | 2013-03-15 | 2017-07-18 | Amgen Inc. | Inhibitory polypeptides specific to WNT inhibitors |
| TW201605896A (en) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | GITR antigen binding proteins |
| CA2923145A1 (en) | 2013-09-05 | 2015-03-12 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
| WO2015087187A1 (en) | 2013-12-10 | 2015-06-18 | Rinat Neuroscience Corp. | Anti-sclerostin antibodies |
| CN105085679B (en)* | 2014-04-25 | 2019-01-11 | 上海津曼特生物科技有限公司 | The anti-RANKL antibody of full source of people |
| US10156562B2 (en) | 2014-05-16 | 2018-12-18 | Amgen Inc. | Assay for detecting Th1 and Th2 cell populations |
| US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| WO2016077451A1 (en) | 2014-11-12 | 2016-05-19 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| AU2016205197B2 (en) | 2015-01-08 | 2021-10-21 | Biogen Ma Inc. | LINGO-1 antagonists and uses for treatment of demyelinating disorders |
| US10441644B2 (en) | 2015-05-05 | 2019-10-15 | The Regents Of The University Of California | H3.3 CTL peptides and uses thereof |
| MA43814A (en) | 2016-03-08 | 2018-11-28 | Janssen Biotech Inc | ANTI-GITR ANTIBODIES, METHODS AND USES |
| AU2017294772B2 (en) | 2016-07-14 | 2024-05-02 | Scholar Rock, Inc. | TGFB antibodies, methods, and uses |
| JP6884858B2 (en) | 2016-10-21 | 2021-06-09 | アムジエン・インコーポレーテツド | Pharmaceutical product and its manufacturing method |
| EA201990557A1 (en)* | 2016-10-28 | 2019-09-30 | Эли Лилли Энд Компани | ANTI-RANKL ANTIBODIES AND THEIR APPLICATION |
| US20200131518A1 (en) | 2017-03-14 | 2020-04-30 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
| AU2019243848B2 (en) | 2018-03-26 | 2025-01-02 | Amgen Inc. | Total afucosylated glycoforms of antibodies produced in cell culture |
| WO2021062372A1 (en) | 2019-09-26 | 2021-04-01 | Amgen Inc. | Methods of producing antibody compositions |
| WO2021247892A1 (en) | 2020-06-04 | 2021-12-09 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
| KR20230087539A (en) | 2020-10-15 | 2023-06-16 | 암젠 인크 | Relative Unbound Glycans in Antibody Production Methods |
| CA3222409A1 (en) | 2021-06-07 | 2022-12-15 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
| EP4341298A4 (en)* | 2021-06-22 | 2025-04-16 | University of Virginia Patent Foundation | Compositions and methods for detecting and regulating fibronectin-integrin interactions and signaling |
| EP4413377A1 (en) | 2021-10-05 | 2024-08-14 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| AR130281A1 (en)* | 2022-08-24 | 2024-11-20 | Amgen Inc | ANTI-DRUG ANTIBODIES TESTS |
| AU2024256160A1 (en) | 2023-04-20 | 2025-10-02 | Amgen Inc. | Methods of determining relative unpaired glycan content |
| WO2025038600A1 (en) | 2023-08-14 | 2025-02-20 | Amgen Inc. | Methods for reducing yellow color |
| WO2025101820A1 (en) | 2023-11-08 | 2025-05-15 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998046751A1 (en)* | 1997-04-16 | 1998-10-22 | Amgen Inc. | Osteoprotegerin binding proteins and receptors |
| WO2000015807A1 (en)* | 1998-09-15 | 2000-03-23 | M & E Biotech A/S | Method for down-regulating osteoprotegerin ligand activity |
| WO2001023549A1 (en)* | 1999-09-29 | 2001-04-05 | University Of Western Australia | Rat osteoclast differentiation factor |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE158316C (en) | ||||
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| AU7432574A (en) | 1973-10-12 | 1976-04-15 | Southam J D | Sprinkler irrigation device |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| US4399216A (en)* | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4474893A (en)* | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| US4816567A (en)* | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4710457A (en) | 1983-06-29 | 1987-12-01 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibody for human hematopoietic glycoproteins and method |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US4710473A (en) | 1983-08-10 | 1987-12-01 | Amgen, Inc. | DNA plasmids |
| US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
| US4740461A (en)* | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| EP0192658A4 (en) | 1984-07-30 | 1987-07-13 | Salk Inst For Biological Studi | Retroviral gene transfer vectors. |
| US4699880A (en)* | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
| US4959314A (en)* | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
| US6410516B1 (en)* | 1986-01-09 | 2002-06-25 | President & Fellows Of Harvard College | Nuclear factors associated with transcriptional regulation |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US5260203A (en)* | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| DE3785186T2 (en) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | BINDING MOLECULE WITH SINGLE POLYPEPTIDE CHAIN. |
| US4912040A (en)* | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| US4892538A (en)* | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5106627A (en)* | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
| US5846534A (en)* | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
| HU215434B (en) | 1988-05-27 | 1999-04-28 | Synergen Inc. | Method for Interleukin-1 Inhibitors to Generate DNA Sequences, Vectors, and Host Cells encoding them |
| US5011472A (en)* | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| FI903489A7 (en)* | 1988-11-11 | 1990-07-10 | Medical Res Council | Ligands containing one moiety, receptors containing these ligands, methods for their preparation and uses of the ligands and receptors |
| US5530101A (en)* | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1990014363A1 (en) | 1989-05-19 | 1990-11-29 | Amgen Inc. | Metalloproteinase inhibitor |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| US5625126A (en)* | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (en) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en)* | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en)* | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en)* | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| JP3356775B2 (en)* | 1990-11-30 | 2002-12-16 | セルトリックス ファーマシューティカルズ， インコーポレイテッド | Use of osteogenic proteins for bone repair by co-combination with TGF-β |
| US5118667A (en)* | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
| CA2068389A1 (en) | 1991-05-13 | 1992-11-14 | Masahiko Sato | Method for inhibiting bone resorption |
| AU733355B2 (en) | 1991-05-14 | 2001-05-10 | Patentsmith Ii, Inc. | Microwave turntable convection heater |
| CA2111348A1 (en) | 1991-06-14 | 1992-12-23 | John S. Logan | Production of human hemoglobin in transgenic pigs |
| WO1993001227A1 (en) | 1991-07-08 | 1993-01-21 | University Of Massachusetts At Amherst | Thermotropic liquid crystal segmented block copolymer |
| MX9204303A (en)* | 1991-07-23 | 1993-11-01 | Rhone Poulenc Rorer Int | REGULATORY FACTOR OF OSTEOCLAST GROWTH. |
| IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
| US5961974A (en)* | 1991-10-25 | 1999-10-05 | Immunex Corporation | Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same |
| AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5234784A (en)* | 1992-04-01 | 1993-08-10 | Eastman Kodak Company | Method of making a projection viewable transparency comprising an electrostatographic toner image |
| US5447851B1 (en)* | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| WO1993021946A1 (en) | 1992-04-30 | 1993-11-11 | Synergen, Inc. | Methods for treating interleukin-1 and tumor necrosis factor mediated diseases |
| US5585479A (en) | 1992-07-24 | 1996-12-17 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human ELAM-I RNA |
| US5578569A (en) | 1993-03-12 | 1996-11-26 | Tam; Cherk S. | Method of increasing bone growth |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| DE69427588T2 (en)* | 1993-09-14 | 2002-04-25 | Merck & Co., Inc. | HUMANE PROTEIN TYROSINPHOSPHATASE DECODING cDNA |
| US6268212B1 (en) | 1993-10-18 | 2001-07-31 | Amgen Inc. | Tissue specific transgene expression |
| US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
| US5641747A (en)* | 1994-07-25 | 1997-06-24 | Temple University-Of The Commonwealth System Of Higher Education | Treatment of osteopetrotic diseases |
| AU4440496A (en) | 1995-02-10 | 1996-08-22 | Smithkline Beecham Corporation | Use of src SH2 specific compounds to treat a bone resorption disease |
| IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
| US20030166097A1 (en) | 1995-03-15 | 2003-09-04 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
| WO1996028546A1 (en) | 1995-03-15 | 1996-09-19 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
| US7094564B1 (en) | 1995-03-15 | 2006-08-22 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
| WO1997000317A1 (en) | 1995-06-07 | 1997-01-03 | Osteosa Inc. | Osteoclast growth regulatory factor |
| WO1997000318A1 (en) | 1995-06-07 | 1997-01-03 | Osteosa Inc. | Osteoclast growth regulatory factor |
| US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| DE69635480T2 (en)* | 1995-06-29 | 2006-08-17 | Immunex Corp., Thousand Oaks | APOPTOSIS INDUCTIVE CYTOKIN |
| US6613544B1 (en)* | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
| US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
| US6046048A (en)* | 1996-01-09 | 2000-04-04 | Genetech, Inc. | Apo-2 ligand |
| US6750091B1 (en)* | 1996-03-01 | 2004-06-15 | Micron Technology | Diode formation method |
| US5981220A (en)* | 1996-03-27 | 1999-11-09 | Human Genome Sciences, Inc. | Epidermal differentiation factor |
| TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
| JPH1057071A (en) | 1996-08-19 | 1998-03-03 | Snow Brand Milk Prod Co Ltd | Novel DNA and method for producing protein using the same |
| KR100643058B1 (en) | 1996-12-03 | 2006-11-13 | 아브게닉스, 인크. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| EP1995318A1 (en)* | 1996-12-13 | 2008-11-26 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| WO1998028423A2 (en) | 1996-12-20 | 1998-07-02 | Board Of Regents, The University Of Texas System | Compositions and methods of use for osteoclast inhibitory factors |
| FR2757507B1 (en) | 1996-12-20 | 1999-01-29 | Inst Francais Du Petrole | PARAXYLENE SEPARATION PROCESS COMPRISING ADSORPTION WITH WATER INJECTION AND CRYSTALLIZATION |
| US6271349B1 (en)* | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
| DE69740107D1 (en)* | 1996-12-23 | 2011-03-10 | Immunex Corp | RECEPTOR ACTIVATOR OF NF-KAPPA B, RECEPTOR IS A MEMBER OF THE TNF RECEPTOR SUPERFAMILY |
| EP0911342B2 (en)* | 1997-04-15 | 2013-05-22 | Daiichi Sankyo Company, Limited | Novel protein and process for producing the same |
| US5843678A (en)* | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
| US6316408B1 (en)* | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| CA2229449A1 (en) | 1997-04-25 | 1998-10-25 | Takeda Chemical Industries, Ltd. | Novel receptor protein and its use |
| CA2288351A1 (en) | 1997-05-01 | 1998-11-05 | Amgen Inc. | Chimeric opg polypeptides |
| AU7705098A (en) | 1997-05-29 | 1998-12-30 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like protein 8 |
| US6087555A (en) | 1997-10-15 | 2000-07-11 | Amgen Inc. | Mice lacking expression of osteoprotegerin |
| US6790823B1 (en) | 1998-04-23 | 2004-09-14 | Amgen Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
| ATE412746T1 (en)* | 1998-05-14 | 2008-11-15 | Immunex Corp | METHOD FOR INHIBITING THE EFFECT OF OSTEOCLASTS |
| US6210924B1 (en) | 1998-08-11 | 2001-04-03 | Amgen Inc. | Overexpressing cyclin D 1 in a eukaryotic cell line |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| AU6078500A (en) | 1999-07-09 | 2001-01-30 | Amgen, Inc. | Combination therapy for conditions leading to bone loss |
| JP2003516718A (en) | 1999-07-29 | 2003-05-20 | メダレックス インク | Human monoclonal antibody against HER2 / neu |
| IL142900A0 (en) | 1999-09-03 | 2002-04-21 | Amgen Inc | Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
| US20030144187A1 (en) | 1999-09-03 | 2003-07-31 | Colin R. Dunstan | Opg fusion protein compositions and methods |
| US20030103978A1 (en)* | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
| CA2400929C (en) | 2000-02-23 | 2011-05-31 | Amgen Inc. | Antagonistic selective binding agents of osteoprotegerin binding protein |
| WO2002024896A2 (en)* | 2000-09-22 | 2002-03-28 | Immunex Corporation | Screening assays for agonists or antagonists of receptor activat or of nf-kb |
| US20030017151A1 (en)* | 2001-05-17 | 2003-01-23 | Dougall William C. | Therapeutic use of rank antagonists |
| JP2005515159A (en)* | 2001-06-06 | 2005-05-26 | イミュネックス・コーポレーション | Use of RANK antagonists to treat cancer |
| DE60235989D1 (en) | 2001-06-26 | 2010-05-27 | Amgen Fremont Inc | ANTIBODIES AGAINST OPGL |
| US7084257B2 (en)* | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| JP4761710B2 (en) | 2002-04-05 | 2011-08-31 | アムジェン インコーポレイテッド | Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors |
| US9401875B2 (en) | 2012-06-01 | 2016-07-26 | Nippon Telegraph And Telephone Corporation | Packet transfer processing method and packet transfer processing device |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998046751A1 (en)* | 1997-04-16 | 1998-10-22 | Amgen Inc. | Osteoprotegerin binding proteins and receptors |
| WO2000015807A1 (en)* | 1998-09-15 | 2000-03-23 | M & E Biotech A/S | Method for down-regulating osteoprotegerin ligand activity |
| WO2001023549A1 (en)* | 1999-09-29 | 2001-04-05 | University Of Western Australia | Rat osteoclast differentiation factor |
| Title |
|---|
| FULLER K ET AL: "TRANCE IS NECESSARY AND SUFFICIENT FOR OSTEOBLAST-MEDIATED ACTIVATION OF BONE RESORPTION IN OSTEOCLASTS", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 188, no. 5, 1998, pages 997 - 1001, XP000876582, ISSN: 0022-1007* |
| See also references ofWO03086289A2* |
| TAKAYANAGI H ET AL: "T-CELL-MEDIATED REGULATION OF OSTEOCLASTOGENESIS BY SIGNALLING CROSS-TALK BETWEEN RANKL AND IFN-GAMMA", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 408, 30 November 2000 (2000-11-30), pages 600 - 605, XP002907421, ISSN: 0028-0836* |
| TSUKII K ET AL: "Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 246, no. 2, 19 May 1998 (1998-05-19), pages 337 - 341, XP002169940, ISSN: 0006-291X* |
| Publication number | Publication date |
|---|---|
| AU2003243139B2 (en) | 2007-06-21 |
| US20100209435A1 (en) | 2010-08-19 |
| US8367063B2 (en) | 2013-02-05 |
| US20120156725A1 (en) | 2012-06-21 |
| US20040023313A1 (en) | 2004-02-05 |
| PL375041A1 (en) | 2005-11-14 |
| US20130164292A1 (en) | 2013-06-27 |
| JP5594982B2 (en) | 2014-09-24 |
| US20130171168A1 (en) | 2013-07-04 |
| JP2005200421A (en) | 2005-07-28 |
| WO2003086289A2 (en) | 2003-10-23 |
| CA2481074A1 (en) | 2003-10-23 |
| EP1494714A2 (en) | 2005-01-12 |
| US20110052604A1 (en) | 2011-03-03 |
| JP2005534622A (en) | 2005-11-17 |
| EP2314316A1 (en) | 2011-04-27 |
| WO2003086289A3 (en) | 2004-01-22 |
| US8455629B2 (en) | 2013-06-04 |
| JP2012188451A (en) | 2012-10-04 |
| US7718776B2 (en) | 2010-05-18 |
| JP4761710B2 (en) | 2011-08-31 |
| MXPA04009681A (en) | 2005-01-11 |
| AU2003243139A1 (en) | 2003-10-27 |
| JP2009242402A (en) | 2009-10-22 |
| JP2008239624A (en) | 2008-10-09 |
| Publication | Publication Date | Title |
|---|---|---|
| EP1494714A4 (en) | Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors | |
| IL165256A0 (en) | Neutralizing human anti-igfr antibody | |
| IL241874A0 (en) | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors | |
| IL164778A0 (en) | Therapeutic use of selective pde10 inhibitors | |
| EP1635903A4 (en) | Therapeutic ultrasound system | |
| AU2003256813A8 (en) | Medical tele-robotic system | |
| EP1497005A4 (en) | Game system | |
| EP1572131A4 (en) | Antibody therapy | |
| EP1511488A4 (en) | Human adam-10 inhibitors | |
| PL377745A1 (en) | An allergen dosage form | |
| ZA200409686B (en) | Bicyclic 6-aklylidene-penems as ?-lactamases inhibitors | |
| IL166344A0 (en) | Device for tectile stimulation | |
| EP1598368A4 (en) | Anti-pci neutralizing antibodies | |
| GB2388557B (en) | Treatment system | |
| ZA200409691B (en) | Heterotricyclyl 6-alkylidene-penems as ß-lactamase inhibitors | |
| AU2003268731A8 (en) | Game system | |
| AU2003287016A8 (en) | Human sarcoma-associated antigens | |
| IL172511A0 (en) | Specific human antibodies | |
| AU2003302077A8 (en) | Freeze concentration system | |
| GB0312305D0 (en) | Amusement device | |
| AU2003297196A8 (en) | Teething devices | |
| AU2003231937A8 (en) | Therapeutic methods | |
| GB0312122D0 (en) | Therapeutic method | |
| GB0224735D0 (en) | Immunisation system | |
| HK1067893A (en) | Neutralizing human anti-igfr antibody |
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase | Free format text:ORIGINAL CODE: 0009012 | |
| 17P | Request for examination filed | Effective date:20041028 | |
| AK | Designated contracting states | Kind code of ref document:A2 Designated state(s):AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR | |
| AX | Request for extension of the european patent | Extension state:AL LT LV MK | |
| A4 | Supplementary search report drawn up and despatched | Effective date:20080205 | |
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) | Owner name:MEDAREX, INC. Owner name:AMGEN INC. | |
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) | Owner name:MEDAREX, INC. Owner name:AMGEN INC. | |
| 17Q | First examination report despatched | Effective date:20080523 | |
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) | Owner name:MEDAREX, L.L.C. Owner name:AMGEN INC. | |
| STAA | Information on the status of an ep patent application or granted ep patent | Free format text:STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN | |
| 18D | Application deemed to be withdrawn | Effective date:20151103 |